 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||||
| PS433540/ DARA |
Hypertension/ Diabetic Nephropathy |
Pharmacopeia |  |
||||
| PS291822/ CXCR2 |
COPD/ Neutrophilic Asthma |
Schering-Plough | |
||||
| PS540446/ p38 |
Psoriasis/ Rheumatoid Arthritis |
Bristol-Myers Squibb | |
||||
| PS178990/ SARM |
Muscle Wasting |
Pharmacopeia | |
||||
| PS095760 | Oncology | Schering-Plough | |
||||
| PS386113 | Inflammation | Schering-Plough | |
||||
| PS948115 | Respiratory | Schering-Plough | |
||||
| PS873266 | Inflammation | Celgene | |
||||
| PS248288 | Metabolic Diseases |
Schering-Plough | |
||||
| PS031291/ CCR1 |
Arthritis/MS | Pharmacopeia | |
||||
| PS015146 | Undisclosed | Schering-Plough | |
||||
| JAK3 | Immunological/ Inflammation |
Wyeth | |
||||
| JAK3 | Topical Derm/Ocular |
Pharmacopeia | |
||||
|
|||||||
The company has a broad portfolio of clinical and preclinical candidates under development internally or with partners including nine clinical compounds in Phase 2 or Phase 1 development addressing hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline.
In addition to the above programs, Pharmacopeia is working with its partners on other research programs, which are expected to drive the Company’s development portfolio going forward.
) |
|
DARA – A First in Class Dual Acting Receptor (AT1 /ETA) Antagonist PS433540 possesses two clinically validated mechanisms of action in a single compound and is designed to be a significant step forward in the management and treatment of several cardiovascular disease states. |
 |
) |
|
Dermatology & Ocular Disease JAK3 A member of the Janus family of tyrosine protein kinases, JAK3 plays a critical role in T-cell proliferation via cytokine signaling pathways. Local administration of a selective JAK3 inhibitor represents a potential therapeutic approach for T-cell and cytokine mediated dermatological and ocular diseases. |
|
) |
|
Arthritis/MS CCR1 CCR1 is a member of the chemokine receptor family and is involved in the trafficking of T-cells and monocytes to specific sites of inflammation, such as the myelin sheath and the arthritic synovium. |
|
